DE3751036D1 - Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen. - Google Patents

Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen.

Info

Publication number
DE3751036D1
DE3751036D1 DE3751036T DE3751036T DE3751036D1 DE 3751036 D1 DE3751036 D1 DE 3751036D1 DE 3751036 T DE3751036 T DE 3751036T DE 3751036 T DE3751036 T DE 3751036T DE 3751036 D1 DE3751036 D1 DE 3751036D1
Authority
DE
Germany
Prior art keywords
carnitine
medicament
manufacture
treatment
pharmaceutical substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751036T
Other languages
English (en)
Other versions
DE3751036T2 (de
Inventor
Alfred Stracher
Leo Kesner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE3751036D1 publication Critical patent/DE3751036D1/de
Application granted granted Critical
Publication of DE3751036T2 publication Critical patent/DE3751036T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE3751036T 1987-01-15 1987-04-16 Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen. Expired - Fee Related DE3751036T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/003,888 US4866040A (en) 1986-01-06 1987-01-15 Aminocarnitine directed pharmaceutical agents

Publications (2)

Publication Number Publication Date
DE3751036D1 true DE3751036D1 (de) 1995-03-16
DE3751036T2 DE3751036T2 (de) 1995-09-21

Family

ID=21708080

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751036T Expired - Fee Related DE3751036T2 (de) 1987-01-15 1987-04-16 Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen.

Country Status (4)

Country Link
US (1) US4866040A (de)
EP (1) EP0279887B1 (de)
JP (1) JPS63174936A (de)
DE (1) DE3751036T2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
IT1230141B (it) * 1989-05-03 1991-10-14 Fidia Spa Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
US5015627A (en) * 1990-07-20 1991-05-14 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
IT1306129B1 (it) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
US20090196914A1 (en) * 2002-11-14 2009-08-06 Optime Therapeutics, Inc. Liposomal l-carnitine
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2005124563A2 (en) * 2004-06-12 2005-12-29 Ceptor Corporation Compounds and kits for treating muscle disorders and methods of use thereof
EP1805207A1 (de) * 2004-09-29 2007-07-11 Ceptor Corporation Behandlung traumatischer bzw. degenerativer neurologischer, otologischer oder ophthalmologischer krankheiten mit zielgerichteten proteaseinhibitoren
US20080039531A1 (en) * 2005-06-13 2008-02-14 Alfred Stracher Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders
JP5227182B2 (ja) * 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
US10583104B2 (en) 2014-08-06 2020-03-10 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE354851B (de) * 1970-02-18 1973-03-26 Haessle Ab
US4320110A (en) * 1972-11-06 1982-03-16 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
US3929756A (en) * 1973-11-21 1975-12-30 Univ Brandeis Synthetically produced tridecapeptide having the same activity as the hypothalamic substance, neurotensin
IT1156840B (it) * 1978-06-27 1987-02-04 Sigma Tau Ind Farmaceuti Acil derivati della carnitina
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
JPS56147718A (en) * 1980-04-16 1981-11-16 Sumitomo Chem Co Ltd Acidic protease inhibitor and antiulcerative composed thereof
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
US4742081A (en) * 1986-01-06 1988-05-03 Alfred Stracher Carnitine coupled pharmaceutical agents

Also Published As

Publication number Publication date
JPS63174936A (ja) 1988-07-19
EP0279887A2 (de) 1988-08-31
DE3751036T2 (de) 1995-09-21
US4866040A (en) 1989-09-12
EP0279887A3 (en) 1990-08-22
EP0279887B1 (de) 1995-02-01

Similar Documents

Publication Publication Date Title
DE3751036D1 (de) Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen.
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
DE122007000002I1 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
RU93058261A (ru) Гетероциклические амины, используемые в терапии астмы и воспаления респираторного тракта
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE68905205D1 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.
DE69435194D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
GR3018009T3 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained.
ATA293589A (de) Neue chinolinsulfonaminoderivate und verfahren zu deren herstellung sowie pharmazeutische zusammensetzung
DE69407419D1 (de) 2' oder 3' -deoxy- und 2' -dideoxy-beta-l-pentafuranonukleoside, verfahren zur herstellung und anwendung in der therapie, insbesondere als antivirale wirkstoffe
ATA309588A (de) Neue kristallform von ciclosporin, verfahren zu ihrer herstellung, diese kristallform enthaltende pharmazeutische zusammensetzung und verwendung dieser kristallform
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69620582D1 (de) Verwendung von WISMUTVERBINDUNGEN zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden
ATA69888A (de) Neue substituierte benzamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die diese benzamide enthalten
PT86572A (de) Polymer-komplexe verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
ATA900894A (de) Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
ATE112276T1 (de) Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
DE3773716D1 (de) Verfahren zur herstellung von monosodiumsalz und dessen monohydrat von 1-beta-d-arabinofuranosylcytosin-5'stearylphosphat und diese enthaltende pharmazeutische zusammensetzung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee